327 related articles for article (PubMed ID: 32708835)
1. Economic Evaluation of Population-Based
Manchanda R; Sun L; Patel S; Evans O; Wilschut J; De Freitas Lopes AC; Gaba F; Brentnall A; Duffy S; Cui B; Coelho De Soarez P; Husain Z; Hopper J; Sadique Z; Mukhopadhyay A; Yang L; Berkhof J; Legood R
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708835
[TBL] [Abstract][Full Text] [Related]
2. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Genetic Testing for All Women Diagnosed with Breast Cancer in China.
Sun L; Cui B; Wei X; Sadique Z; Yang L; Manchanda R; Legood R
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406611
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
Lipton JH; Zargar M; Warner E; Greenblatt EE; Lee E; Chan KKW; Wong WWL
Hum Reprod; 2020 Feb; 35(2):434-445. PubMed ID: 32099994
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
9. Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
Lim KK; Yoon SY; Mohd Taib NA; Shabaruddin FH; Dahlui M; Woo YL; Thong MK; Teo SH; Chaiyakunapruk N
Appl Health Econ Health Policy; 2018 Jun; 16(3):395-406. PubMed ID: 29572724
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
[TBL] [Abstract][Full Text] [Related]
11. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract][Full Text] [Related]
12. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
Hurry M; Eccleston A; Dyer M; Hoskins P
Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
[TBL] [Abstract][Full Text] [Related]
13. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
Koldehoff A; Danner M; Civello D; Rhiem K; Stock S; Müller D
Value Health; 2021 Feb; 24(2):303-312. PubMed ID: 33518037
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
Tuffaha HW; Mitchell A; Ward RL; Connelly L; Butler JRG; Norris S; Scuffham PA
Genet Med; 2018 Sep; 20(9):985-994. PubMed ID: 29300376
[TBL] [Abstract][Full Text] [Related]
17. Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
Michaelson-Cohen R; Cohen MJ; Cohen C; Greenberg D; Shmueli A; Lieberman S; Tomer A; Levy-Lahad E; Lahad A
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551598
[TBL] [Abstract][Full Text] [Related]
18. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
19. A cost-utility analysis of
Lertwilaiwittaya P; Tantai N; Maneeon S; Kongbunrak S; Nonpanya N; Hurst ACE; Srinonprasert V; Pithukpakorn M
Front Public Health; 2023; 11():1257668. PubMed ID: 38162618
[TBL] [Abstract][Full Text] [Related]
20. Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
Hoskins P; Eccleston A; Hurry M; Dyer M
Gynecol Oncol; 2019 Apr; 153(1):87-91. PubMed ID: 30704745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
